Treatment of Male Partners in Recurrent Bacterial Vaginosis
For males whose female partners experience recurrent bacterial vaginosis, treat the male partner with metronidazole 400 mg orally twice daily for 7 days PLUS clindamycin 2% cream applied to penile skin twice daily for 7 days, while simultaneously treating the female partner with standard first-line therapy. 1, 2
Evidence Supporting Partner Treatment
The traditional CDC stance that treating male partners does not prevent BV recurrence 3, 4 has been overturned by a landmark 2025 randomized controlled trial that demonstrated clear benefit:
- The 2025 StepUp trial showed that combined treatment of both partners reduced BV recurrence from 63% to 35% within 12 weeks (absolute risk reduction of 2.6 recurrences per person-year, P<0.001). 2
- This trial was stopped early by the data safety monitoring board because treating women alone was clearly inferior to treating both partners. 2
- The evidence strongly suggests sexual exchange of BV-associated organisms between partners, supporting the rationale for partner treatment. 2
Specific Treatment Protocol
For the Male Partner:
- Metronidazole 400 mg orally twice daily for 7 days 1, 2
- AND clindamycin 2% cream applied to penile skin twice daily for 7 days 1, 2
For the Female Partner:
- Standard first-line therapy: metronidazole 500 mg orally twice daily for 7 days 3, 5, 6
- Alternative options include metronidazole gel 0.75% intravaginally or clindamycin preparations 3
Critical Patient Instructions
Both partners must adhere to these precautions:
- Avoid all alcohol during metronidazole treatment and for 24 hours after completion to prevent disulfiram-like reactions (nausea, vomiting, flushing). 3, 1
- Refrain from unprotected intercourse for at least 14 days to allow treatment to take effect. 1
- Complete the full 7-day course even if symptoms resolve earlier. 1, 2
Expected Adverse Effects in Treated Males
Common side effects include:
These are generally mild and self-limited. 2
When Partner Treatment Is Indicated
Partner treatment should be considered specifically for:
- Recurrent BV cases (defined as multiple episodes despite appropriate treatment of the female partner). 1, 5
- Couples in monogamous relationships where reinfection from the male partner is suspected. 2
- Women who have experienced treatment failure with standard therapy alone. 5
Important Clinical Caveats
- This represents a paradigm shift: Six older randomized trials showed no benefit to partner treatment 1, but the 2025 trial used a more comprehensive approach (combined oral and topical therapy) that proved effective. 2
- Partner treatment is not recommended for initial BV episodes—reserve this approach for recurrent cases. 1
- No routine follow-up is needed for asymptomatic male partners, but women should return if symptoms persist or recur. 1
- Recurrence rates remain high (50-80% within one year) even with optimal treatment, possibly due to biofilm formation or poor adherence. 3, 5, 7
Alternative Approach for Recurrent BV in Women
If partner treatment fails or is not feasible: